Recapping BIO International Convention 2026: Biopharma Eyes a Resilient Future
The annual gathering in San Diego showcased the industry's pivot toward complex molecules, flexible manufacturing, and human-based drug discovery — while candid conversations about capital access, deal strategy, and preclinical predictability reflected a sector navigating pressure with optimism.
The BIO International Convention 2026, held June 22–25 at the San Diego Convention Center, drew thousands of biopharma professionals across four days of sessions, partnering meetings, and exhibit floor conversations that captured an industry in transition. BioPharm International© covered the conference from multiple angles — conducting on-site interviews with scientists, executives, legal advisors, and manufacturing experts — and the themes that emerged paint a consistent picture: complexity is rising across pipelines, manufacturing, and deal structures alike, and the companies best positioned for the decade ahead are those building adaptability into every layer of their operations.